Stockscreener 앱 받기
5.73
2.55%
-0.15
시장 영업 전:
5.79
0.06
+1.05%
Vanda Pharmaceuticals Inc 주식(VNDA)의 최신 뉴스
Watch VANDA Pharmaceuticals Berlin Tennis Open / Court 1 | Disney+ - Disney Plus
Why Did Vanda Pharmaceuticals Stock Slide 7% Pre-Market Today? - Stocktwits
Watch VANDA Pharmaceuticals Berlin Tennis Open / Steffi Graf Stadion | Disney+ - Disney Plus
VNDA Stock Soars 40% Overnight After Bysanti Approval: What’s The Next Catalyst And How Much Upside Remains? - Stocktwits
Vanda Stock Draws Heavy Buzz Ahead Of FDA Verdict On Bysanti For Bipolar, Schizophrenia - Stocktwits
Vanda Pharmaceuticals Stock Price Forecast. Should You Buy VNDA? - StockInvest.us
VNDA Stock Rises After Hours On Commercial Launch Of Motion Sickness Drug - Stocktwits
VNDA Stock Rallies After-Hours As FDA Approves Schizophrenia, Bipolar Disorder Drug - Stocktwits
80,000-share RSU grant to Vanda (VNDA) SVP and General Counsel - Stock Titan
Vanda Pharmaceuticals (VNDA) director granted 41,600 RSU shares vesting in 2027 - Stock Titan
Vanda (NASDAQ: VNDA) director awarded 41,600 RSU-based shares - Stock Titan
Vanda Pharmaceuticals (VNDA) director receives 41,600-share RSU award - Stock Titan
Vanda Pharmaceuticals (VNDA) director receives 41,600-share RSU grant - Stock Titan
Vanda Pharmaceuticals (VNDA) grants director 41,600 RSUs vesting in 2027 - Stock Titan
Vanda Pharmaceuticals (VNDA) SVP McGuire reports RSU awards vesting through 2029 - Stock Titan
Vanda Pharma Stock Rises Pre-Market After FDA Accepts Imsidolimab Filing For Rare Skin Disorder - Stocktwits
Vanda Pharmaceuticals 2026 Annual Meeting Results: Director Elections, Auditor Ratification, and Plan Amendment Approved - minichart.com.sg
Vanda (NASDAQ: VNDA) investors approve directors, auditor and equity plan shares - Stock Titan
Earnings call transcript: Vanda Pharmaceuticals misses Q1 2026 forecasts, stock rises - Investing.com
Analysts Offer Insights on Healthcare Companies: Vanda (VNDA), ArriVent BioPharma, Inc. (AVBP) and Medtronic (MDT) - The Globe and Mail
Gastroparesis Market Shows Strong Future Potential with Increasing Industry Investments by 2036 – DelveInsight | Vanda Pharma, Dr. Falk Pharma GmbH, Alfasigma S.p.A., PTC Therapeutics, CinDome Pharma - Barchart.com
Gastroparesis Market Shows Strong Future Potential with - openPR.com
Vanda Pharmaceuticals stock rating reiterated at Buy by H.C. Wainwright - Investing.com
Why did Vanda Pharmaceuticals stock slide 7% pre-market today? - MSN
Earnings call transcript: Vanda Pharmaceuticals Q1 2026 misses EPS forecast, stock drops - Investing.com Nigeria
Vanda Pharmaceuticals (VNDA) Shares Rise 3.75% as Stock Tests Key ResistanceWMA Signal - The Legal Advocate
H.C. Wainwright Maintains Vanda Pharmaceuticals(VNDA.US) With Buy Rating, Maintains Target Price $21 - Moomoo
Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan - GuruFocus
Vanda gets orphan drug status in Japan for imsidolimab By Investing.com - Investing.com Australia
Vanda Pharmaceuticals (VNDA) Secures Orphan Drug Status in Japan - GuruFocus
Vanda gets orphan drug status in Japan for imsidolimab - Investing.com
Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis - Barchart
Vanda a new buy at B. Riley on 'historic discount' - MSN
Vanda Pharmaceuticals Inc (VNDA) Stock Price, Quote, News & History - Benzinga
Vanda Pharmaceuticals Q3 Earnings Preview - MSN
Vanda (VNDA) director donates 25,836 shares of common stock - Stock Titan
VNDA: 2026 revenue guidance raised on new launches, with BYSANTI and NEREUS set to drive future growth - TradingView
How The Vanda Pharmaceuticals (VNDA) Investment Story Is Shifting With BYSANTI And Nereus - Yahoo Finance
Vanda Pharmaceuticals stock (US92178N1054): Regulatory setback, sharp drop and rising short interest - AD HOC NEWS
Vanda: A Long-Term Pharma Growth Idea, Despite Q1 Earnings Miss (NASDAQ:VNDA) - Seeking Alpha
Vanda targets $240M-$290M 2026 revenue as it introduces $10M-$30M NEREUS sales outlook - MSN
HC Wainwright Brokers Lower Earnings Estimates for VNDA - MarketBeat
State Street (VNDA) discloses 3.02M shares, 5.1% ownership on 13G - Stock Titan
Earnings call transcript: Vanda Pharmaceuticals Q1 2026 misses EPS forecast, stock drops By Investing.com - Investing.com South Africa
1.27%
1.43%
자본화:
|
볼륨(24시간):